Virtual Library

Start Your Search

Masao Nakata



Author of

  • +

    P2.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 965)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.16-36 - Adjuvant Chemotherapy is Effective for Completely Resected Stage IB Non-Small Cell Lung Cancer (ID 12659)

      16:45 - 18:00  |  Presenting Author(s): Masao Nakata

      • Abstract
      • Slides

      Background

      The efficacy of adjuvant chemotherapy for completely resected stage IB non-small cell lung cancer (NSCLC) still remains controversial. The Cancer and Leukemia Group B (CALGB) 9633 trial reported that the adjuvant chemotherapy with paclitaxel and carboplatin showed a significant survival advantage in a subset of patients with tumors larger than 4cm in diameter. In Japan, uracil-tegaful (UFT) has been recommended for stage IB NSCLC. The purpose of this study is to compare the efficacy of platinum-based regimens with UFT as the adjuvant chemotherapy for stage IB NSCLC.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Patients who underwent complete resection with systemic nodal dissection for stage IB NSCLC between January 2008 and December 2017 in our hospital were retrospectively studied. Disease stage was defined according to the 6th edition of UICC TNM classification. Patients who underwent sublobar resection or any induction therapy prior to surgery were excluded from this study. This study was conducted with the approval of the Ethics Committee of Kawasaki Medical School.

      4c3880bb027f159e801041b1021e88e8 Result

      There were 135 eligible patients consisting of 91 male and 44 female, with mean age of 72.1 years (range, 43-87 years). Of 135 patients, 59 patients (43.7%) underwent adjuvant chemotherapy (platinum-based 15, UFT 44). Median follow-up period was 37.9 months (range 1.1-107.3 months). Overall survival of patients undergoing adjuvant chemotherapy was significantly better compared with that of patients with surgery alone (p=0.032). There were no differences in recurrence-free survival between the two groups (p=0.470). Patients who underwent adjuvant chemotherapy with platinum-based regimens survived significantly longer than patients who underwent surgery alone (p=0.029). Overall survival of patients with platinum-based regimens tended to be better than that of patients with UFT. In a multivariate analysis including sex, age, histologic type, and tumor size, adjuvant chemotherapy was an independent prognostic factor for overall survival (p=0.037).

      8eea62084ca7e541d918e823422bd82e Conclusion

      Adjuvant chemotherapy, especially with platinum-based regimen, provided a significant survival advantage for completely resected stage IB NSCLC.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.